These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23371380)

  • 1. [Importance and treatment of spasticity in multiple sclerosis : results of the MOVE 1 study].
    Henze T; Flachenecker P; Zettl UK
    Nervenarzt; 2013 Feb; 84(2):214-22. PubMed ID: 23371380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of life.
    Flachenecker P; Henze T; Zettl UK
    Acta Neurol Scand; 2014 Mar; 129(3):154-62. PubMed ID: 24256407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin.
    Zahavi A; Geertzen JH; Middel B; Staal M; Rietman JS
    J Neurol Neurosurg Psychiatry; 2004 Nov; 75(11):1553-7. PubMed ID: 15489386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study.
    Vermersch P
    Neurodegener Dis Manag; 2014; 4(6):407-15. PubMed ID: 25531685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M
    Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis spasticity daily management: retrospective data from Europe.
    Berger T
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):3-7. PubMed ID: 23369053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.
    Rekand T; Grønning M
    J Rehabil Med; 2011 May; 43(6):511-4. PubMed ID: 21533331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).
    Zettl UK; Henze T; Essner U; Flachenecker P
    Eur J Health Econ; 2014 Dec; 15(9):953-66. PubMed ID: 24292503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epidemiology and clinical assessment of spasticity in multiple sclerosis].
    Bensmail D; Vermersch P
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S45-50. PubMed ID: 22721364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.
    Collongues N; Vermersch P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):21-5. PubMed ID: 23369056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.
    Skierlo S; Rommer PS; Zettl UK
    Acta Neurol Scand; 2017 Apr; 135(4):394-399. PubMed ID: 27283842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients.
    Rommer PS; Kamin F; Abu-Mugheisib M; Koehler W; Hoffmann F; Winkelmann A; Benecke R; Zettl UK
    CNS Neurosci Ther; 2016 Jan; 22(1):74-9. PubMed ID: 26584946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
    Stampacchia G; Gerini A; Mazzoleni S
    NeuroRehabilitation; 2016 Apr; 38(4):385-93. PubMed ID: 27061166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and treatment of spasticity reported by multiple sclerosis patients.
    Rizzo MA; Hadjimichael OC; Preiningerova J; Vollmer TL
    Mult Scler; 2004 Oct; 10(5):589-95. PubMed ID: 15471378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
    Mehta LR; McDermott MP; Goodman AD; Schwid SR
    Mult Scler; 2010 Feb; 16(2):248-51. PubMed ID: 20028712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spasticity in multiple sclerosis: results of a patient survey.
    Oreja-Guevara C; González-Segura D; Vila C
    Int J Neurosci; 2013 Jun; 123(6):400-8. PubMed ID: 23297730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.